Lyell Immunopharma, Inc. (LYEL) — 10-Q Filings

10-Q Filings (6)

• Lyell Narrows Losses Amid R&D Cuts, Boosts Cash with PIPE Financing — Nov 12, 2025 Risk: medium
  Lyell Immunopharma, Inc. reported a net loss of $38.846 million for the three months ended September 30, 2025, a decrease from the $44.583 million net loss in t
• Lyell Narrows Losses Amid R&D Cuts, Cash Burn Continues — Aug 12, 2025 Risk: high
  Lyell Immunopharma, Inc. (LYEL) reported a net loss of $42.684 million for the three months ended June 30, 2025, a decrease from the $45.809 million net loss in
• Lyell Immunopharma Files Q1 2025 10-Q — May 13, 2025 Risk: low
  Lyell Immunopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including
• Lyell Immunopharma Files Q3 2024 10-Q Report — Nov 7, 2024 Risk: medium
  Lyell Immunopharma, Inc. filed its Q3 2024 10-Q report on November 7, 2024, covering the period ending September 30, 2024. The company, focused on pharmaceutica
• Lyell Immunopharma Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Lyell Immunopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses, but specific dollar amounts
• Lyell Immunopharma Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk:
  Lyell Immunopharma, Inc. (LYEL) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Lyell Immunopharma, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX